Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose
of IPI-504 in patients with non-small cell lung cancer (NSCLC). The study will examine how
IPI-504 is absorbed, distributed, metabolized and eliminated by the body. The study will also
evaluate the anti-tumor activity of IPI-504.